SCHEMBL19935508

SCHEMBL19935508

CC(=O)OCc1cc(=O)c2c(OCC(COc3cccc4oc(COC(C)=O)cc(=O)c34)OC(C)=O)cccc2o1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GPR35 Q9HC97 2/20 0.48
▸ LMNA P02545 1/20 0.48
▸ TDP1 Q9NUW8 1/20 0.48
▸ MEN1 O00255 2/20 0.47
▸ KMT2A Q03164 2/20 0.47
▸ HIF1A Q16665 1/20 0.47
▸ HTR2B P41595 2/20 0.39
▸ ABCG2 Q9UNQ0 9/20 0.39
▸ BCHE P06276 1/20 0.39
▸ ACHE P22303 1/20 0.39
▸ ALDH1A1 P00352 2/20 0.37
▸ KDM4E B2RXH2 1/20 0.37
▸ TP53 P04637 1/20 0.37
▸ CYP3A4 P08684 1/20 0.37
▸ CYP2D6 P10635 1/20 0.37
▸ CYP2C9 P11712 1/20 0.37
▸ CYP2C19 P33261 1/20 0.37
▸ HSD17B10 Q99714 1/20 0.37
▸ HPGD P15428 1/20 0.37
▸ ABCB1 P08183 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25472693 0.96 GPR35 (0.45) GPR35LMNATDP1MEN1KMT2A
SCHEMBL27109018 0.91 GPR35 (0.44) GPR35LMNATDP1MEN1KMT2A
SCHEMBL25669914 0.89 GPR35 (0.50) GPR35LMNATDP1MEN1KMT2A
SCHEMBL19935517 0.89 GPR35 (0.62) GPR35LMNATDP1MEN1KMT2A
SCHEMBL27108981 0.88 GPR35 (0.49) GPR35LMNATDP1MEN1KMT2A
SCHEMBL19935516 0.88 GPR35 (0.49) GPR35LMNATDP1MEN1KMT2A
SCHEMBL24600024 0.85 GPR35 (0.47) GPR35LMNATDP1MEN1KMT2A
SCHEMBL27109008 0.84 GPR35 (0.46) GPR35LMNATDP1MEN1KMT2A
SCHEMBL8661688 0.82 GPR35 (0.72) GPR35LMNATDP1MEN1KMT2A
SCHEMBL26848984 0.81 GPR35 (0.55) GPR35LMNATDP1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240067635-A1 CROMOLYN DERIVATIVES AND USES THEREOF THE GENERAL HOSPITAL CORPORATION 2024-02-29 — — US disclosed
US-20240067635-A1 CROMOLYN DERIVATIVES AND USES THEREOF THE GENERAL HOSPITAL CORPORATION 2024-02-29 — — US disclosed
EP-3506894-B1 MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES MASSACHUSETTS GEN HOSPITAL (US) 2023-08-23 — — EP disclosed
US-20230226017-A1 METHODS OF TREATING A CORONAVIRUS INFECTION MASSACHUSETTS GEN HOSPITAL (US) 2023-07-20 — — US disclosed
US-11679095-B2 Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases THE GENERAL HOSPITAL CORPORATION (US) 2023-06-20 — — US disclosed
US-20230149345-A1 METHODS OF TREATMENT OF CORONAVIRUS-INDUCED INFLAMMATION CONDITIONS THE GENERAL HOSPITAL CORPORATION 2023-05-18 — — US disclosed
US-20220218652-A1 METHODS OF TREATING CYTOKINE RELEASE SYNDROME AZTHERAPIES, INC. 2022-07-14 — — US disclosed
WO-2022146914-A1 CROMOLYN DERIVATIVES AND USES THEREOF THE GENERAL HOSPITAL CORPORATION (US) 2022-07-07 — — WO disclosed
US-20210059977-A1 COMBINATION THERAPIES FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS THE GENERAL HOSPITAL CORPORATION 2021-03-04 — — US disclosed
WO-2019199776-A1 COMBINATION THERAPIES FOR THE TREATMENT OF AMYOTROPIC LATERAL SCLEROSIS AND RELATED DISORDERS THE GENERAL HOSPITAL CORPORATION (US) 2019-10-17 — — WO disclosed
US-20190240194-A1 MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES THE GENERAL HOSPITAL CORPORATION 2019-08-08 — — US disclosed
WO-2018045217-A1 MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES THE GENERAL HOSPITAL CORPORATION (US) 2018-03-08 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20190240194-A1 MACROPHAGES/MICROGLIA IN NEURO-INFLAMMATION ASSOCIATED WITH NEURODEGENERATIVE DISEASES CD68, PRNP, HTT GPR35 1528/4885LMNA 755/4885TDP1 3376/4885
US-20240067635-A1 CROMOLYN DERIVATIVES AND USES THEREOF PRNP, HTT, CLN6 GPR35 1991/4885LMNA 111/4885TDP1 978/4885
US-11679095-B2 Macrophages/microglia in neuro-inflammation associated with neurodegenerative diseases CD68, PRNP, HTT GPR35 1528/4885LMNA 755/4885TDP1 3376/4885
US-20220218652-A1 METHODS OF TREATING CYTOKINE RELEASE SYNDROME CMKLR1, CMKLR2, GSS GPR35 393/4885LMNA 3211/4885TDP1 3763/4885
US-20230149345-A1 METHODS OF TREATMENT OF CORONAVIRUS-INDUCED INFLAMMATION CONDITIONS C3AR1, IL5, C5 GPR35 359/4885LMNA 3678/4885TDP1 4796/4885
US-20230226017-A1 METHODS OF TREATING A CORONAVIRUS INFECTION CPA3, CMA1, ACE2 GPR35 1712/4885LMNA 2521/4885TDP1 3569/4885
US-20210059977-A1 COMBINATION THERAPIES FOR THE TREATMENT OF AMYOTROPHIC LATERAL SCLEROSIS AND RELATED DISORDERS CLN6, PRNP, RTN3 GPR35 3648/4885LMNA 66/4885TDP1 737/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback